Hamazaki Risa, Uesawa Yoshihiro
Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204-8588, Japan.
Pharmaceuticals (Basel). 2024 Aug 23;17(9):1116. doi: 10.3390/ph17091116.
Taste and smell disorders can worsen the nutritional status of patients receiving chemotherapy and potentially affect drug treatment. However, there is limited knowledge on antineoplastic agents that induce taste and smell disorders. Therefore, we used the U.S. Food and Drug Administration Adverse Event Reporting System database to analyze the characteristics of patients and antineoplastic agents in relation to taste and smell disorders. No gender differences related to the onset of taste and smell disorders were found, whereas older age was identified as a possible risk factor. Among the antineoplastic agent classes, protein kinase inhibitors appeared to be particularly likely to induce taste and smell disorders. According to the cluster and principal component analyses, antineoplastic agents were deemed to induce taste or smell disorders. In addition, antineoplastic agents that decreased or changed these sensations could be classified. These findings might be useful in selecting drugs for patients experiencing similar side effects.
味觉和嗅觉障碍会使接受化疗的患者营养状况恶化,并可能影响药物治疗。然而,关于诱发味觉和嗅觉障碍的抗肿瘤药物的知识有限。因此,我们使用美国食品药品监督管理局不良事件报告系统数据库,分析与味觉和嗅觉障碍相关的患者及抗肿瘤药物的特征。未发现味觉和嗅觉障碍发病存在性别差异,而年龄较大被确定为一个可能的风险因素。在抗肿瘤药物类别中,蛋白激酶抑制剂似乎特别容易诱发味觉和嗅觉障碍。根据聚类分析和主成分分析,抗肿瘤药物被认为会诱发味觉或嗅觉障碍。此外,可对降低或改变这些感觉的抗肿瘤药物进行分类。这些发现可能有助于为有类似副作用的患者选择药物。